VERO Venus Concept

Venus Concept Inc. Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes

Venus Concept Inc. Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes

TORONTO, June 26, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that the Company has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes. The Company’s inclusion in these indexes will become effective today after the US market close.

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes.

“We are pleased to join these three Russell indexes,” said Domenic Serafino, Chief Executive Officer and Director of Venus Concept. “We continue to believe the long-term opportunity remains extremely compelling for us as a leading player in both the global minimally invasive/non-invasive medical aesthetics market and the minimally invasive surgical hair restoration market.”

FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes.

For more information on the Russell indexes and the Russell indexes reconstitution, please visit the “Russell Reconstitution” section on the .

About Venus Concept

Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 29 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept’s product portfolio consists of 10 aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, and Venus Bliss. Venus Concept’s hair restoration systems includes NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “1933 Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “1934 Act”). Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about the expected synergies and cost savings from our merger with Venus Concept Ltd. and restructuring program; our financial performance; the growth in demand for our systems and other products; and general economic conditions, including the global economic impact of COVID-19, involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under Part I Item 1A—“Risk Factors” in our most recent Annual Report on Form 10-K, Part II Item 1A—“Risk Factors” in our Form 10-Q for the quarter ended March 31, 2020, and in other documents we may file with the SEC. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.

Investor Relations Contact:

Westwicke Partners on behalf of Venus Concept:

Mike Piccinino, CFA

 
EN
26/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Venus Concept

 PRESS RELEASE

Venus Concept Announces Second Quarter 2025 Financial Results

Venus Concept Announces Second Quarter 2025 Financial Results TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of Financial Results & Recent Progress: Total revenue for the second quarter of $15.7 million, down 5% year-over-year and up 15% quarter-over-quarter U.S. revenue up $0.4 million, or 5%, year-over-year driven by growth in cash systems sales of $1.0 million, or 23%, year...

 PRESS RELEASE

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial ...

Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025 TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to partici...

 PRESS RELEASE

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transacti...

Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction Further reduction of outstanding debt by Madryn Asset Management improves the Company’s balance sheet position TORONTO, July 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that, on June 30, 2025, the Company exchanged $6.5 million of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP (“Madryn”) for 325,651 shares of its Series Y preferred stock. Following the transactio...

 PRESS RELEASE

Venus Concept Announces Closing of Up To $3.45 Million Registered Dire...

Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of ...

 PRESS RELEASE

Venus Concept Announces Up To $3.45 Million Registered Direct Offering...

Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules $1.15 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the exercise in full of unregistered short-term warrants TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch